David de Gijsel

Dr. David de Gijsel


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
DGDavid de Gijsel
David de Gijsel
CRC. Fordham von Reyn
C. Fordham von Reyn

22 February 2019 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
EPEskild Petersen
Eskild Petersen
MRMartin Rao
Martin Rao
GIGiuseppe Ippolito
Giuseppe Ippolito
Gina GualanoGina Gualano
Gina Gualano
Chakaya Muhwa JeremiahChakaya Muhwa Jeremiah
Chakaya Muhwa Jeremiah
AZAlimuddin Zumla
Alimuddin Zumla
Tuberculosis today remains the world’s number one cause of death from an infectious disease ( WHO, 2018a x WHO, 2018a WHO. World Health Organization. Global tuberculosis report. ; 2018 ( https://www.who.int/tb/publications/global_report/en/. [Accessed 29th December 2018]) Google Scholar See all References WHO, 2018a ). According to data from the World Health Organization Global Tuberculosis Report ( WHO, 2018a x WHO, 2018a WHO. World Health Organization. Global tuberculosis report. ; 2018 ( https://www.who.int/tb/publications/global_report/en/. [Accessed 29th December 2018]) Google Scholar See all References WHO, 2018a ), global efforts to control tuberculosis are not on target to achieve the goals of the WHO Strategy to end the global tuberculosis epidemic by 2030 ( WHO, 2015 x WHO, 2015 WHO. WHO End TB Strategy: global strategy and targets for tuberculosis prevention, care and control after 2015. WHO, Geneva; 2015 ( http://www.who.int/tb/post2015_strategy/en/. [Accessed 30th December 2018]) Google Scholar See all References WHO, 2015 ). In 2017, an estimated 10 million people (5.8 million men, 3.2 million women, and 1 million children) developed tuberculosis and 4 million people with tuberculosis remained undiagnosed and untreated. There were 558,000 new cases of drug-resistant TB, 82% of which were multi-drug resistant tuberculosis (MDR-TB-resistance to isoniazid and rifampicin), and 8.5% has extensively drug resistant TB (XDR-TB -MDR-TB plus resistance to both a fluoroquinolone and an injectable) ( WHO, 2018a x WHO, 2018a WHO. World Health Organization. Global tuberculosis report. ; 2018 ( https://www.who.int/tb/publications/global_report/en/. [Accessed 29th December 2018]) Google Scholar See all References WHO, 2018a ).

30 August 2024 in Viruses
Verified
Journal Article
Open access
PDF file
EBElyse Bianchet
Elyse Bianchet
DGDavid de Gijsel
David de Gijsel
LTLizbeth Del Toro-Mejias
Lizbeth Del Toro-Mejias
TSThomas J Stopka
Thomas J Stopka
RHRandall Hoskinson
Randall Hoskinson
PFPeter D. Friedmann
Peter D. Friedmann
Hepatitis C virus (HCV) disproportionately affects people who inject drugs (PWID). Although HCV has become universally curable since the arrival of direct-acting antivirals, barriers exist to facilitating care and cure in this historically hard-to-reach population, including limited testing and healthcare services and healthcare stigma, issues that are compounded in rural areas. Telehealth is effective in increasing access to HCV care and cure, but innovative approaches of testing and care are required to fully address the need among rural PWID, which led to our study examining a mobile telehealth model for treating HCV. In this commentary, we discuss lessons learned delivering telehealth on a mobile unit, important factors for consideration when designing a mobile intervention, and we suggest an ideal model to increase access to HCV testing and treatment and other services for rural PWID.

20 September 2023 in Journal of Participatory Medicine
Verified
Journal Article
Open access
SBShoshana H Bardach
Shoshana H Bardach
APAmanda N. Perry
Amanda N. Perry
EEElizabeth Eccles
Elizabeth Eccles
ECElizabeth A Carpenter-Song
Elizabeth A Carpenter-Song
RFRyan C Fowler
Ryan C Fowler
DGDavid de Gijsel
David de Gijsel
Background: People who inject drugs are experiencing syndemic conditions with increasing risk of infection with hepatitis C (HCV) and HIV. However, rates of accessing HCV and HIV testing and treatment among people who inject drugs are low for various reasons, including the criminalization of drug use, which leads to a focus on treating drug use rather than caring for drug users. For many people who inject drugs, health care becomes a form of structural violence, resulting in traumatic experiences, fear of police violence, unmet needs, and avoidance of medical care. There is a clear need for novel approaches to health care delivery for people who inject drugs. Objective: This study aimed to analyze the process of a multidisciplinary team—encompassing health care professionals, community representatives, researchers, and people with lived experience using drugs—that was formed to develop a deep understanding of the experiences of people who inject drugs and local ecosystem opportunities and constraints to inform the cocreation of low-barrier, innovative HCV or HIV care in a rural community. Given the need for innovative approaches to redesigning health care, we sought to identify challenges and tensions encountered in this process and strategies for overcoming these challenges. Methods: Analysis was based on an in-depth review of meeting notes from the project year, followed by member-checking with the project team to revise and expand upon the challenges encountered and strategies identified to navigate these challenges. Results: Challenges and tensions included: scoping the project, setting the pace and urgency of the work, adapting to web-based work, navigating ethics and practice of payment, defining success, and situating the project for sustainability. Strategies to navigate these challenges included: dedicated effort to building personal and meaningful connections, fostering mutual respect, identifying common ground to make shared decisions, and redefining successes. Conclusions: While cocreated care presents challenges, the resulting program is strengthened by challenging assumptions and carefully considering various perspectives to think creatively and productively about solutions.

2 September 2020 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
DGDavid de Gijsel
David de Gijsel
MDMartha DesBiens
Martha DesBiens
ETElizabeth A Talbot
Elizabeth A Talbot
DLDavid J Laflamme
David J Laflamme
SCStephen Conn
Stephen Conn
BCBenjamin P Chan
Benjamin P Chan
Background: Healthcare systems and public health agencies use different methods to measure the impact of substance use (SU) on population health. We studied the ability of systems to accurately capture data on drug use-associated infective endocarditis (DUA-IE). Methods: We conducted a retrospective analysis of patients with IE discharge diagnosis from an academic medical center, 2011–2017, comparing data from hospital Electronic Health Record (EHR) to State Uniform Hospital Discharge Data Set (UHDDS). To identify SU we developed a composite measure. Results: EHR identified 472 IE discharges (430 of these were captured in UHDDS); 406 (86.0%) were correctly coded based on chart review. IE discharges increased from 57 to 92 (62%) from 2012 to 2017. Hospitalizations for the subset of DUA-IE identified by any measure of SU increased from 10 to 54 (440%). Discharge diagnosis coding identified 128 (60.7%) of total DUA-IE hospitalizations. The composite measure identified an additional 65 (30.8%) DUA-IE hospitalizations and chart review an additional 18 (8.5%). Conclusions: The failure of discharge diagnosis coding to identify DUA-IE in 40% of hospitalizations demonstrates the need for better systems to capture the impact of SU. Collaborative data sharing could help improve surveillance responsiveness to address an emerging public health crises.

6 December 2025 in Viruses
Verified
Journal Article
Open access
PDF file
APAmanda N. Perry
Amanda N. Perry
EEElizabeth Eccles
Elizabeth Eccles
SBShoshana H Bardach
Shoshana H Bardach
AHAlastair Huntley
Alastair Huntley
RFRyan C Fowler
Ryan C Fowler
DGDavid de Gijsel
David de Gijsel
Background: People who inject drugs (PWID) have a higher risk of contracting hepatitis C (HCV) than the general population, but these individuals are often poorly served by traditional healthcare systems. The elimination of HCV as a threat to public health relies on the treatment of this population. Novel care models designed with input from PWID may help to better align care to the needs of PWID. Methods: We designed and implemented a community-based, point-of-care testing program for HCV delivered by a syringe service program, combined with facilitated access to a healthcare provider, care navigation, and financial incentives. We collected participant demographics and drug use patterns, testing and treatment history, and communication preferences. Descriptive analyses include the number of people tested between 15 October 2021 and 1 February 2025, their seropositivity rate, and the number who completed pre-treatment laboratory tests, completed treatment and achieved cure by sustained virologic response (SVR12) by 1 August 2025. Results: The program engaged 464 unique individuals, of whom 98 (21.1%) had a known diagnosis of HCV. Of 389 unique individuals who underwent point of care (POC) HCV antibody (Ab) testing, including 31 with a known prior diagnosis of HCV, 97 (24.9%) had a positive result. Of 439 unique individuals who underwent POC HIV Ab testing, only 1 had a positive result. Of 164 individuals with either a positive POC HCV Ab test or a known HCV diagnosis, 66 completed pre-treatment laboratory tests, identifying 52 viremic participants. Of those, 35 started and completed treatment. Among those who completed treatment, 9 (25.7%) achieved SVR12, 3 (8.6) failed to achieve SVR12, and 23 (65.7%) had outstanding laboratory orders for SVR12 determination. Conclusions: An incentivized, community-based, point-of-care testing program with facilitated linkage to care successfully engaged a high-risk population in HCV and HIV testing and treatment. However, substantial attrition occurred at each step of the care cascade, particularly at SVR12 determination. Additional strategies are needed to optimize retention throughout the entire care cascade.